Skip to content
Search AI Powered

Latest Stories

Lung cancer patients to benefit from ground-breaking new drug on NHS

Thousands of lung cancer patients in England will benefit from a ground-breaking new drug that can reduce the risk of relapse.

This follows a deal brokered by NHS England and approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for atezolizumab therapy to treat non-small cell lung cancer (NSCLC).


More than 850 patients are expected to be eligible for the drug in the first year, rising to more than 1000 in the third year.

It is the first immunotherapy approved for patients with early-stage NSCLC who have undergone surgery and chemotherapy.

Clinical trials have shown that atezolizumab can reduce the risk of cancer relapse or death by 34 per cent in patients with early-stage NSCLC.

NHS chief Amanda Pritchard Chief Executive of NHS England Amanda Pritchard (Photo by Tom Nicholson-WPA Pool/Getty Images)

Amanda Pritchard, chief executive of NHS England, said: “By making atezolizumab available at the earliest opportunity NHS patients now have a very exciting new treatment which has the potential to dramatically reduce their risk of cancer relapse.

“The NHS has a strong track record of securing rapid access to innovative, trailblazing treatments for our patients, and this is the latest agreement that places a brand new treatment in the hands of frontline NHS staff, supporting them to continue to deliver world-class patient care."

The NHS Long Term Plan has set out a target to ensure that 55,000 more people survive their cancer each year.

Sajid Javid Health secretary Sajid Javid

Commenting on the announcement, health and social care secretary Sajid Javid said: “This breakthrough will be life-changing for hundreds of people and marks a significant development in our war on cancer.

“A big thank you to NHS England, Roche, the MHRA and the teams of scientists and medical experts who have made this life-saving deal a reality.”

Dame June Raine, MHRA chief executive, said the regulator is “working to ensure that patients receive earlier access to promising cancer treatments.”

More For You

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less